For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a serious condition, the introduction of this treatment and the formulated version represents a genuine advancement . These groundbreaking therapies stabilize the transthyretin protein, halting its harmful build-up and reducing the impact of the condition . Patients are now